Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q2 2023 Earnings Presentation

40 slides from Neurocrine Biosciences's earnings presentation, Aug 1, 2023

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q2 2023 Corporate Presentation August 1, 2023 Nasdaq: NBIX

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our

  3. Slide 3: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth * Raised 2023 Annual Net ~600,000 Sales Guidance to are affected by Tardive $1.77B to $1.82B Dyskinesia (TD) in the U.S. (Tardive Dyskinesia Only) (~70% are undiagnosed) R&D Focus Robust Multiple Compounds in Mid- to Late-Stage Studies • Neurology • N

  4. Slide 4: Q2 2023 Highlights and 2023 Key Milestones and Activities

    Q2 2023 Highlights and 2023 Key Milestones and Activities Q2 2023 / Recent Highlights 2023 Key Milestones and Activities ▪ INGREZZA® (valbenazine) Net Product Sales of $440M 2023 − YoY Sales Growth of 26% vs. Q2 2022 ▪ Potential sNDA Approval of Valbenazine for the Treatment of Chorea Associated wit

  5. Slide 5: Significant Milestones in the Second Half of 2023

    Significant Milestones in the Second Half of 2023 Valbenazine Crinecerfont NBI-921352 NBI-1065846 Chorea in Huntington’s Disease Congenital Adrenal Hyperplasia Focal Onset Seizures Anhedonia in MDD Registrational Data in PDUFA Adult and Pediatric Phase 2 Data Phase 2 Data (August 20th) Studies (Earl

  6. Slide 6: Multiple Molecules and Mechanisms to Treat Intractable Diseases

    Multiple Molecules and Mechanisms to Treat Intractable Diseases NEUROLOGY NEUROENDOCRINOLOGY Chorea in SCN8A Adrenal Huntington’s Tardive Focal Onset Developmental Parkinson’s Endometriosis Uterine Fibroids Insufficiency Disease (HD) Dyskinesia Seizures (FOS) and Epileptic Disease FDA APPROVED FDA A

  7. Slide 7: Strong Pipeline Momentum

    Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Chorea in Huntington’s Disease PDUFA Date = August 20th, 2023 valbenazine* Dyskinetic Cerebral Palsy Registrational Top-Line Data Expected in 2024 Reviewing Full Data Set from Phase 2 Study to NBI-827

  8. Slide 8: Q2 2023 Financial Summary

    Q2 2023 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q2 2023 Q2 2022 Highlights / Comments Revenue $453 $378 Q2 2023 INGREZZA Sales of $440M Driven by Record New - Product Sales, Net 446 352 Patient Starts - Collaboration Revenue 6 26 Non-GAAP R&D Expense $122 $120 Continued

  9. Slide 9: Raised 2023 INGREZZA Sales and Reaffirmed Operating Expense Guidance

    Raised 2023 INGREZZA Sales (TD Indication Only) and Reaffirmed Operating Expense Guidance 2023 Previous 2023 Current Item ($ Millions) 2022 Actuals Comments Guidance Range Guidance Range INGREZZA Net Product Sales1 $1,428 $1,670 - $1,770 $1,770 - $1,820 Raising Range GAAP R&D Expense2 $464 $550 - $5

  10. Slide 10: Corporate Sustainability

    Corporate Sustainability Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Comprehensive Quality Industry-leading employee Improving profit

  11. Slide 11: Our Medicines, Our Patients

    © NEYROCRINE Our Medicines, Our Patients

  12. Slide 12: Commercial Products Fueling Pipeline Investment

    Commercial Products Fueling Pipeline Investment In the U.S. In the U.S. and EU * ‡ TARDIVE DYSKINESIA ENDOMETRIOSIS ADRENAL INSUFFICIENCY In Europe ‡ † PARKINSON'S DISEASE UTERINE FIBROIDS Congenital Adrenal Hyperplasia *Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Jap

  13. Slide 13: INGREZZA

    INGREZZA (valbenazine) capsules NEUROCRINE BIOSCIENCES

  14. Slide 14: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($MM) $500 Q2 2023 Sales of $440M Represents 26% Year-Over-Year Growth vs. Q2 2022 $450 $440 $410 $399 $400 $376 $350 $350 $301 $303 $300 $287 $250 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q1 '23 14

  15. Slide 15: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  16. Slide 16: Nascent TD Market Presents Significant Opportunity

    Nascent TD Market Presents Significant Opportunity Approximately 30% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Only half of diagnosed patients receive treatment for TD with a VMAT2 inhibitor like INGREZZA people in the U.S. ~30% TD Diagnosed Increasing Antipsychotic Prescr

  17. Slide 17: Driving Long-Term Growth for INGREZZA

    Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach

  18. Slide 18: Neurology Pipeline

    © NEVROCRINE Neurology Pipeline

  19. Slide 19: sNDA for Valbenazine for Chorea in Huntington Disease Accepted by FDA

    Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease Accepted by FDA Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In

  20. Slide 20: Valbenazine: Registrational Program in Dyskinetic Cerebral Palsy

    Valbenazine*: Registrational Program in Dyskinetic Cerebral Palsy Dyskinetic Cerebral Palsy (DCP) A form of cerebral palsy (CP) that affects ~15% of the approximately 500,000 to 1M people in the U.S. diagnosed with the disease. Can result in a range of developmental delays, physical difficulties and

  21. Slide 21: NBI-921352: Selective Nav1.6 Inhibitor in Ongoing Phase 2 Studies

    NBI-921352*: Selective Nav 1.6 Inhibitor in Ongoing Phase 2 Studies; Phase 2 FOS Study Fully Enrolled with Top-Line Data in Q4 2023 Adult Focal Onset Seizures (FOS) Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the mo

  22. Slide 22: Neuroendocrinology Pipeline

    Neuroendocrinology Pipeline

  23. Slide 23: Classic Congenital Adrenal Hyperplasia (CAH)

    Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue

  24. Slide 24: Congenital Adrenal Hyperplasia Disease Mechanism

    Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 24

  25. Slide 25: Crinecerfont Potentially Meets Challenges of the Standard of Care

    Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT

  26. Slide 26: Potential Paradigm Shift in the Treatment of CAH

    Potential Paradigm Shift in the Treatment of CAH With Top-Line Results Expected For Each Study in Early Q4 2023 Crinecerfont* Phase 3 Global Adult Registrational Study: Enrollment Complete Phase 3 Global Pediatric Registrational Study: Enrollment Complete Potent Orally Active Selective Well-Tolerate

  27. Slide 27: Neuropsychiatry Pipeline

    (5) NEUROCRINE BIOSCIENCES

  28. Slide 28: Valbenazine: Registrational Programs in Adjunctive Treatment of Schizophrenia

    Valbenazine*: Registrational Programs in Adjunctive Treatment of Schizophrenia With Top-Line Data from 1st Study in 2024 Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A serious, chronic m

  29. Slide 29: Potential First-in-Class Neuropsychiatry Programs

    Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies NBI-1065846* Anhedonia in Major Depressive Disorder Top-line Data Expected in Q4 2023 (Study Fully Enrolled) Inadequate Response to Treatment in N

  30. Slide 30: NBI-1065846: GPR139 Agonist

    NBI-1065846*: GPR139 Agonist Anhedonia in Major Depressive Disorder NBI-1065846 260 million+ people worldwide are Potent first-in-class investigational GPR139 agonist • Once weekly affected by major depressive disorder • Potential adjunctive treatment (MDD). GPR139 is an orphan receptor in the haben

  31. Slide 31: NBI-1065845: AMPA Potentiator

    NBI-1065845*: AMPA Potentiator Inadequate Response to Treatment NBI-1065845 in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Once daily U.S. who live with MDD do not respond • Potential adjunctive treatment to available antidepressants

  32. Slide 32: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor

    Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagnosed • No titration requirement with schizophrenia Hypofu

  33. Slide 33: Developing Novel Muscarinic Receptor Agonist Portfolio

    Developing Novel Muscarinic Receptor Agonist Portfolio Neurocrine Biosciences Advancing Muscarinic Portfolio Clinical studies, include: ➢ Initiated Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 agonist, as a potential treatment for schizophrenia ✓ NBI-1117568 offers the potential

  34. Slide 34: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth * Raised 2023 Annual Net ~600,000 Sales Guidance to are affected by Tardive $1.77B to $1.82B Dyskinesia (TD) in the U.S. (Tardive Dyskinesia Only) (~70% are undiagnosed) R&D Focus Robust Multiple Compounds in Mid- to Late-Stage Studies • Neurology • N

  35. Slide 35: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  36. Slide 36: Condensed Consolidated Statements of Operations

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in millions, except per share data) Revenues: Net product sales Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process rese

  37. Slide 37: Condensed Consolidated Balance Sheets

    CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) NEUROCRINE BIOSCIENCES, INC. (unaudited) Cash, cash equivalents and marketable securities Other current assets Total current assets Deferred tax assets Debt securities available-for-sale Right-of-use assets Equity security investments Property and

  38. Slide 38: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended Six Months Ended Sune 30, June 30, (in millions, except per share data) 2023 2022 2023, 2022 GAAP net income (loss) $ 955 $ (169) $ 18.9 $ (3.0) Adjustments: Stock-based compensation expe

  39. Slide 39: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (in millions) GAAP cost of revenues Adjustments: ‘Non-cash amortization related to acquired intangible assets Non-GAAP cost of revenues (ox millions) GAAP R&D Adjustments: Stock-based compensation expense

  40. Slide 40: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q2 2023 Corporate Presentation August 1, 2023 Nasdaq: NBIX

Neurocrine Biosciences — Q2 2023 Earnings Presentation on 6ix